公开信息显示，骏亚科技成立于2005年11月22日，上市日期为2017年9月12日，主营业务包括印制电路板的研发、生产和销售及印制电路板的表面贴装等。 单季度看，2024年第四季度骏亚科技实现营业收入5.92亿元，同比增长4.54%，环比下降7.70%；归母净亏损为1.39亿元，同比下降885.00%，环比下降 9497.84%；扣非归母净亏损为1.28亿元，同比下降610.22%，环比下降3061.94%。 财务指标方面，2024年骏亚科技毛利率为15.04%，同比下降5.01个百分点；净利率为-6.58%，同比下降9.40个百分点。 费用方面，2024年骏亚科技期间费用为3.83亿元，同比减少2019.97万元；期间费用率为16.32%，同比下降0.29个百分点。其中，销售费用同比增长1.17%， 管理费用同比减少7.84%，研发费用同比减少5.80%，财务费用同比减少0.26%。 此外，2024年骏亚科技经营活动产生的现金流量净额为4.05亿元，同比增长82.13%。截至2024年末，骏亚科技总资产为33.48亿元，同比下降2.2%；归母净 资产为13.41亿元，同比下降11.3%。 4月26日，广东骏 ...

本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 事件1： 高纯化学品和光刻胶持续放量，大额商誉减值及新增折旧拖累24年业绩 点击注册小程序 查看完整报告 特别申明： 公司发布2024年年报。2024年，公司实现营收14.35亿元，同比增长10.44%；实现归母净利润-1.80亿元， 同比减少1312%；实现扣非后归母净利润-1.71亿元，同比减少491%。2024Q4，公司单季度实现营收3.75 亿元，同比增长10.11%，环比增长2.21%；实现归母净利润-1.80亿元，同比亏损扩大2265%，环比由盈转 亏。 事件2： 公司发布2025年一季报。2025Q1，公司单季度实现营收3.70亿元，同比增长12.17%，环比减少1.27%；实 现归母净利润4350万元，同比增长582%，环比扭亏为盈。 点评： 拟发行股 ...

Core Viewpoint - Starlight Co., Ltd. has faced regulatory scrutiny due to significant discrepancies between its 2024 performance forecast and actual results, leading to a warning letter from the Guangdong Securities Regulatory Bureau [1][2]. Financial Performance - In 2024, Starlight Co., Ltd. reported revenue of 192 million yuan, representing a year-on-year increase of 27.22% [4]. - The company incurred a net loss attributable to shareholders of 30.98 million yuan, with the loss widening by 136.35%, marking the second consecutive year of losses [1][4]. Regulatory Actions - The Guangdong Securities Regulatory Bureau issued a warning letter to Starlight Co., Ltd. due to the failure to disclose the potential for delisting risk in a timely manner, violating disclosure regulations [2][3]. - Key executives, including the chairman and CFO, were held responsible for the company's non-compliance with disclosure obligations [2]. Internal Control and Audit - The annual audit report highlighted deficiencies in the company's internal controls related to investment management, prompting corrective actions [3]. - The auditing firm provided an unqualified opinion with an emphasis on the issues identified [2]. Business Segments and Acquisitions - Starlight Co., Ltd. operates in various sectors, including LED lighting, UV disinfection, automotive lighting, lithium battery production equipment, and information security [4]. - The lithium battery production equipment segment accounted for 29.43% of total revenue, while the newly added information security segment generated only 6.34 million yuan, contributing to the company's losses [4][5]. - The company acquired 51% stakes in two firms, aiming to enhance its information security capabilities, although the expected synergies have not yet materialized [5]. Research and Development - Despite an increase in R&D personnel from 85 to 113, R&D expenses significantly decreased from 15.51 million yuan in 2023 to 4.51 million yuan in 2024 due to fewer projects [5].

Core Viewpoint - The domestic beauty market shows a stark contrast, with Proya becoming the first domestic brand to exceed 10 billion yuan in revenue, while Shanghai Jahwa faces a significant decline in net profit, marking a challenging period for the company [1][2]. Financial Performance - Shanghai Jahwa reported a revenue of 5.679 billion yuan for 2024, a year-on-year decrease of 13.93% [1]. - The company experienced a net loss of 833 million yuan, a staggering decline of 266.6% compared to the previous year, marking the largest loss since the company began publishing annual reports [1][2]. - The overseas business revenue was 1.415 billion yuan, down 11.43% year-on-year, contributing to the overall decline in profit [2][3]. Strategic Adjustments - The new CEO, Lin Xiaohai, initiated significant organizational reforms aimed at shifting the business model from "channel-driven" to "brand-driven" [1][9]. - The company undertook strategic adjustments, including reducing inventory in department stores and transitioning from an agency model to a self-operated model for online distributors, which negatively impacted current revenue [2][3]. Goodwill Impairment - The company recorded a goodwill impairment of 610 million yuan related to the acquisition of the UK infant care brand "Tommee Tippee," which was purchased for nearly 2 billion yuan in 2017 [2][3]. - The impairment was attributed to factors such as low birth rates overseas, intensified competition in the infant product category, and reduced inventory by distributors [3]. Market Position - Shanghai Jahwa's revenue has significantly lagged behind Proya, which has seen its revenue gap widen to 5 billion yuan, with Proya achieving over 10 billion yuan in annual revenue [6]. - The beauty segment of Shanghai Jahwa has been particularly underperforming, with a revenue decline of 29.81%, while the personal care segment remains the largest contributor at 2.379 billion yuan, down 3.42% [6]. Online vs. Offline Sales - The company's online revenue for 2024 was 2.539 billion yuan, a decrease of 9.66%, while offline revenue was 3.136 billion yuan, down 16.97% [6]. - The online gross margin increased by 1.8 percentage points to 63.58%, compared to 52.78% for offline channels, indicating a more favorable cost structure for online sales [6][7]. Future Outlook - Despite the poor performance in 2024, the first quarter of 2025 showed signs of recovery, with total revenue of 1.704 billion yuan, a year-on-year decline of 10.59% but a quarter-on-quarter increase of 41.73% [12]. - The company aims to enhance its online capabilities and adapt to changing consumer behaviors by focusing on interest-based e-commerce and developing content-driven online operations [10].

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price adjusted to RMB 32.50 [1][9]. Core Insights - The company has cleared goodwill impairment risks and is expanding its plasma collection stations through both organic growth and acquisitions, establishing a foundation for future growth. The potential impact of tariffs on imported albumin may benefit domestic albumin products [1][9]. - The company reported a full-year revenue of RMB 1.74 billion in 2024, a decrease of 34.58%, while net profit increased by 67.18% to RMB 397 million, primarily due to a low base from goodwill impairment in 2023 [1][9]. - The product structure is continuously optimized, with blood product revenue growing by 4.32% to RMB 1.51 billion in 2024, despite a slight decline in gross profit margin [1][9]. Financial Summary - Revenue and profit forecasts for the upcoming years have been adjusted, with 2025 EPS projected at RMB 1.16 and 2026 EPS at RMB 1.33, while a new forecast for 2027 EPS is set at RMB 1.50 [1][9]. - The company is expected to maintain a steady growth trajectory, with plasma collection volume projected to reach 630.6 tons in 2024, reflecting a 10.4% increase [1][9]. - The financial outlook includes a projected net profit of RMB 585 million for 2025, with a net profit margin expected to improve over the years [1][9].

Core Viewpoint - The company *ST Jiyao is facing delisting due to its stock price falling below 1 yuan for 20 consecutive trading days, triggering the Shenzhen Stock Exchange's delisting rules [1] Financial Performance - *ST Jiyao has reported continuous losses for five years, with a cumulative net profit loss exceeding 3.2 billion yuan from 2019 to 2023, and an additional loss of 231 million yuan in the first three quarters of 2024 [3] - By the end of 2024, the company's net assets are projected to be between -1.18 billion yuan and -830 million yuan, indicating financial delisting risks [3] - As of September 30, 2024, the company's debt ratio has risen to 161.77%, with a current ratio of only 0.16 [3] Company Background - The company was originally known as Tonghua Shuanglong Chemical Co., Ltd., primarily producing white carbon black for defense chemicals. It transitioned to the pharmaceutical sector in 2014 through the acquisition of Jinbao Pharmaceutical, forming a dual business model of "chemicals + pharmaceuticals" [6] - After rebranding to Jiyao Holdings in 2017, the company aggressively pursued acquisitions, acquiring over ten companies within three years, covering eight major sectors including pharmaceutical manufacturing, commerce, and research [6] Goodwill and Impairment Issues - The company's aggressive cross-industry expansion has led to significant goodwill risks, with cumulative goodwill impairment exceeding 1.5 billion yuan from 2019 to 2024, directly contributing to net profit losses [7] - In 2019, the company reported revenue of 1.066 billion yuan but incurred a net profit loss of 1.772 billion yuan, with asset impairment accounting for over 70% of the total net profit loss [7] Failed Restructuring Attempts - *ST Jiyao has made multiple unsuccessful attempts at self-rescue through capital operations, including a failed transfer of control to the Jilin Provincial State-owned Assets Management Company in 2019 due to unresolved terms [8] - The company attempted to acquire Xiu Zheng Pharmaceutical, but the deal was terminated due to the significant revenue disparity, leading to a regulatory investigation and a fine of 600,000 yuan [8] - In November 2020, a proposed transfer of control to Bencao Hui Pharmaceutical fell through due to disputes, and a restructuring application in June 2023 was ultimately rejected by the court [9] Recent Developments - On March 19, 2025, *ST Jiyao's stock price first fell below 1 yuan, leading to a continued decline, culminating in the announcement of its delisting on April 23, 2025 [10] - Since the beginning of 2025, at least four other listed companies have also faced similar delisting conditions [10]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，美年健康披露了2024年年报。年报数据显示，报告期内公司实现营收107.02亿元，同比微降 1.76%；归母净利润为2.82亿元，同比下降44.18%；扣非净利润2.52亿元，同比下降45.52%。 结合往期业绩表现看，公司2023年业绩短暂回暖后再度出现回落迹象，颇具信号意义。回顾历史，2019 年至今，美年健康的业绩表现有如过山车，业绩大起大落的背后与公司商誉减值、疫情扰动等密不可 分。而2024年公司并未进行大额商誉减值计提，疫情也早已成为过去时。在此背景下，公司盈利规模仍 未得到显著修复。 在连锁体检机构赛道中，由于体检设备、体检服务、体检服务等明显趋同，难以拉开大的差距，那么门 店的数量以及覆盖城市则成为衡量体检中心在行业中地位的重要指标。为了满足扩张的需求，美年健康 自2011年起便开启了激进并购的模式。 美年健康的发展模式转为体系内孵化，即上市公司先少量参股，一般参股份额在10%左右，余下的股份 则由其成立但在体系之外的并购基金或其他投资人持有。而在培育期中，随着标的体检中心营运逐渐走 上正轨，具备盈利能力，美年健康 ...

Core Viewpoint - Shiji Information plans to acquire 13.50% of Shenzhen Sihon Software Co., Ltd. through a share issuance, which may indicate a continuation of high premium pricing based on historical acquisition patterns [1][2] Group 1: Company Overview - Shenzhen Sihon Software, established in April 2004, specializes in digital solutions for the retail industry, offering products such as smart retail, SaaS, digital operations, and Sihon Pay [1] - In 2023, Sihon Software attempted an IPO on the Beijing Stock Exchange but later terminated it [1] Group 2: Financial Performance - For the first three quarters of 2024, Sihon Software reported a 10.79% year-on-year decline in revenue and a 12.38% decrease in net profit attributable to shareholders [1] - As of September 2024, Shiji Information's goodwill reached 1.194 billion yuan, accounting for 12.5% of total assets, primarily from multiple acquisitions [1] Group 3: Acquisition Context - Historical acquisitions by Shiji Information, such as those of Zhongdian Devices, showed significant premiums due to shareholder differences, suggesting a potential for high premium pricing in the current acquisition [1] - The acquisition of Sihon Software may have limited synergy with Shiji Information's main hotel information business, as evidenced by past integration challenges faced by Alibaba Group with Shiji's retail business [2] Group 4: Financial Risks - In 2019, Shiji Information did not recognize impairment for goodwill related to loss-making subsidiaries, raising concerns about aggressive accounting practices [2] - As of Q3 2024, Shiji Information's cash reserves decreased by 276 million yuan, and while the acquisition will not directly consume cash, it may dilute earnings per share [2]

4月22日，《华夏时报》记者致电采访星徽股份证券部，工作人员表示与泽宝技术诉讼案件目前还在审 理过程中。而对于公司跨境电商业务发展状况等其他问题，其表示不方便回应。 星徽股份陷入亏损泥沼，源自公司2018年收购深圳市泽宝创新技术有限公司（下称"泽宝技术"）转型跨 境电商后，在2021年突然遭遇泽宝技术大量亚马逊账号被封杀，此后又被海外多国追缴税款并收取罚 金，从而连续多年拖累公司业绩。星徽股份也因此陷入与泽宝技术的法律纠纷，至今案件仍在审理中。 对于2024年亏损，星徽股份方面称，主要原因一是对泽宝技术计提商誉减值2.74亿元；二是与泽宝技术 原股东等相关诉讼计提预计负债1.23亿元。 跨界收购阴霾未散 星徽股份的亏损，要从公司一起跨界收购行动说起。 2018年，主营五金制品的星徽股份看中跨境电商的高增长潜力，宣布以15.3亿元跨界收购深圳跨境大卖 泽宝技术。彼时的泽宝技术正处于高速发展期，是全球电商巨头亚马逊平台最大中国商户，主要业务是 通过亚马逊向海外消费者销售蓝牙音频、小家电等产品。2017年，泽宝技术营业收入为17.43亿元，是 星徽股份当年营收的三倍不止。 签署收购协议的同时，星徽股份还和泽宝技术原 ...

近日，乐普医疗（300003.SZ）发布2024年年度和2025年一季度业绩报告，公司业绩持续下滑。 从2023年开始，乐普医疗业绩就明显失速了，营收利润等核心指标都出现下降，如今这样的趋势还在延 续。 公开资料显示，乐普医疗成立于1999年，是国内最早从事心脏介入医疗器械研发制造的企业之一。经过 二十余年的发展，乐普医疗已成为国内领先的心血管大健康产业平台，主营业务涵盖医疗器械、药品、 医疗服务及健康管理三大板块 业绩数据显示，2024年，乐普医疗实现营业收入61.03亿元，同比下降23.52%；净利润2.47亿元，同比 大跌80.37%；扣非净利润2.21亿元，同比大跌80.28%，这一下滑程度创下乐普医疗自2009年上市以来新 低。 2025年一季度的业绩表现，乐普医疗同样不太好。数据显示，2025年一季度营收17.36亿元，同比下降 9.67%；净利润3.79亿元，同比下降21.44%；扣非净利润3.37亿元，同比下降26.08%。业绩颓势还在延 续。 从年报业绩来看，2025年1月，乐普医疗曾发布2024年度业绩预告，当时公司预计全年净利润为2.65亿 元至3.95亿元。 从乐普医疗最终业绩表现看， ...